Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 ...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

Dexcom Inc. DXCM, a leading glucose monitor manufacturer, has enabled direct Apple Inc.’s AAPL Watch connectivity for its G7 model in the United States. What Happened: The new feature allows G7 users ...

Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the ...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Dec. 24, 2025 ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2024 performance, along with a series of favorable coverage ...

DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...